While non-steroidal MRAs have not yet been investigated in type 1 diabetes, based on their observed benefits in type 2 diabetes and their mechanism of action, similar kidney-protective effects are anticipated, emphasising the need for dedicated studies with finerenone in people with type 1 diabetes and CKD, including their use in combination with other repurposed therapies such as SGLT2i and GLP1-RAs
In some settings it may be used in injectable or wound-healing protocols
Do not use if you are pregnant, may become pregnant, or are breastfeeding
Standard FDA criteria apply in Oklahoma: BMI 30 (obese) qualifies, or BMI 27 (overweight) with a weight-related condition (type 2 diabetes, hypertension, sleep apnea, high cholesterol, PCOS)
Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid
10mg vs 5mg vs 15mg: Choosing a Vial Size Choosing between AVPs 5mg, 10mg, and 15mg GLP-3 RT vials comes down to matching total peptide supply to the length and intensity of a research protocol the 10mg vial sits at the midpoint, offering more total content than the 5mg option while requiring a shorter management window than the 15mg
